This is a summary of the European public assessment report (EPAR) for Trevicta. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Trevicta. For practical information about using Trevicta, patients should read the package leaflet or contact their doctor or pharmacist.
Therapeutic Indication
### Therapeutic indication Trevicta, a 3 monthly injection, is indicated for the maintenance treatment of schizophrenia in adult patients who are clinically stable on 1 monthly paliperidone palmitate injectable product.
Therapeutic Area (MeSH)
ATC Code
N05AX13
ATC Item
paliperidone
Pharmacotherapeutic Group
Psycholeptics
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| paliperidone palmitate | N/A | 帕利哌酮 |
EMA Name
Trevicta (previously Paliperidone Janssen)
Medicine Name
Trevicta (previously Paliperidone Janssen)
Aliases
N/A
